CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease-Reference-Cited by-同舟云学术

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

Published:2023-05-05 Issue:7 Volume:102 Page:1731-1738
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Shen Yao-jia,Zhang Yi,Chang Jie,Wang Hua-feng,Ye Xing-nong,Zhu Li,Jin Jie,Zhu Hong-hu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05213-6.pdf

Reference31 articles.

1. Opatz S, Bamopoulos SA, Metzeler KH et al (2020) The clinical mutatome of core binding factor leukemia. Leukemia 34:1553–1562

2. Speck NA, Gilliland DG (2002) Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2:502–513

3. Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447

4. Borthakur G, Kantarjian H (2021) Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 11:114

5. Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051–1062

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony‐stimulating factor chemotherapy as a first‐line therapy for newly diagnosed acute myeloid leukemia: A propensity score–matched analysis;Cancer;2024-03-12